Insider · CIK 0001585160

Landry Robert E

Reports to the SEC for 3 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001585160

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-15	CYTKCYTOKINETICS INCS Sale	Director	SSale	−1,000 sh	$72.13	−$72.1K	8,184
2026-09-11	CYTKCYTOKINETICS INCS Sale	Director	SSale	−1,000 sh	$74.66	−$74.7K	9,184
2026-05-27	CYTKCYTOKINETICS INCA Award	Director	AAward	+2,851 sh	—	—	10,184
2026-05-27	CYTKCYTOKINETICS INC · Non-Qualified Stock Option (Right to Buy)A Award	Director	AAward	+4,301 sh	—	—	4,301
2026-01-12	ZYMEZymeworks Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+11.5K sh	—	—	11,500
2026-01-12	ZYMEZymeworks Inc. · Restricted Stock UnitA Award	Director	AAward	+7,700 sh	—	—	7,700
2025-08-11	ZYMEZymeworks Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+62K sh	—	—	62,000
2025-05-14	CYTKCYTOKINETICS INCA Award	Director	AAward	+7,333 sh	—	—	7,333
2025-05-14	CYTKCYTOKINETICS INC · Non-Qualified Stock Option (Right to Buy)A Award	Director	AAward	+10.9K sh	—	—	10,880
2025-02-10	CYTKCYTOKINETICS INC · Non-Qualified Stock Option (Right to Buy)A Award	Director	AAward	+25.5K sh	—	—	25,538
2024-02-02	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+400 sh	$378.98	+$152K	23,974
2024-02-02	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−281 sh	$956.65	−$269K	23,693
2024-02-02	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−400 sh	—	—	11,787
2024-01-31	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+400 sh	$378.98	+$152K	23,856
2024-01-31	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−282 sh	$953.42	−$269K	23,574
2024-01-31	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−400 sh	—	—	12,187
2024-01-24	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+500 sh	$378.98	+$189K	23,808
2024-01-24	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−352 sh	$951.26	−$335K	23,456
2024-01-24	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−500 sh	—	—	12,587
2024-01-23	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+1,100 sh	$378.98	+$417K	24,084
2024-01-23	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−776 sh	$948.50	−$736K	23,308
2024-01-23	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−1,100 sh	—	—	13,087
2024-01-17	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+500 sh	$378.98	+$189K	23,338
2024-01-17	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−354 sh	$932.34	−$330K	22,984
2024-01-17	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−500 sh	—	—	14,187
2024-01-12	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+800 sh	$378.98	+$303K	23,406
2024-01-12	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−568 sh	$928.18	−$527K	22,838
2024-01-12	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−800 sh	—	—	14,687
2024-01-04	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+500 sh	$378.98	+$189K	22,948
2024-01-04	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−342 sh	$917.05	−$314K	22,606
2024-01-04	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−500 sh	—	—	15,487
2024-01-03	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+1,100 sh	$378.98	+$417K	23,136
2024-01-03	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−688 sh	$912.30	−$628K	22,448
2024-01-03	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−1,100 sh	—	—	15,987
2024-01-02	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+650 sh	$378.98	+$246K	22,457
2024-01-02	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−421 sh	$888.34	−$374K	22,036
2024-01-02	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−650 sh	—	—	17,087
2023-12-28	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+850 sh	$378.98	+$322K	22,419
2023-12-28	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−612 sh	$884.88	−$542K	21,807
2023-12-28	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−850 sh	—	—	17,737
2023-12-27	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+750 sh	$378.98	+$284K	22,111
2023-12-27	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−542 sh	$872.21	−$473K	21,569
2023-12-27	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−750 sh	—	—	18,587
2023-12-13	REGNREGENERON PHARMACEUTICALS, INC.M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	+1,000 sh	$378.98	+$379K	22,084
2023-12-13	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−723 sh	$871.12	−$630K	21,361
2023-12-13	REGNREGENERON PHARMACEUTICALS, INC. · Non-Qualified Stock Option (right to buy)M Exercise/Conversion	EVP Finance CFO	MExercise/Conversion	−1,000 sh	—	—	19,337
2023-12-12	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−6,381 sh	$856.71	−$5.47M	21,084
2023-12-11	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−669 sh	$844.09	−$565K	30,017
2023-12-11	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−2,552 sh	$844.09	−$2.15M	27,465
2023-12-08	REGNREGENERON PHARMACEUTICALS, INC.F Tax Payment	EVP Finance CFO	FTax Payment	−1,013 sh	$843.79	−$855K	30,686

Recent filings

Accepted (ET)
Sep 154
Landry Robert E0001061983-26-000095
SEC(opens sec.gov)
Sep 114
Landry Robert E0001061983-26-000093
SEC(opens sec.gov)
May 274
Landry Robert E0001061983-26-000056
SEC(opens sec.gov)
Jan 124
Landry Robert E0001193125-26-010859
SEC(opens sec.gov)
Aug 124
Landry Robert E0000950170-25-107543
SEC(opens sec.gov)
May 144
Landry Robert E0001127602-25-014356
SEC(opens sec.gov)
Feb 114
Landry Robert E0001127602-25-003989
SEC(opens sec.gov)
Feb 64
Landry Robert E0001968202-24-000053
SEC(opens sec.gov)
Feb 24
Landry Robert E0001968202-24-000045
SEC(opens sec.gov)
Jan 254
Landry Robert E0001968202-24-000040
SEC(opens sec.gov)

Companies

Address

350 OYSTER POINT BLVD

SOUTH SAN FRANCISCO, CA, 94580